A study of the once-weekly investigational dipeptidyl peptidase-4 omarigliptin reported a clinically meaningful reduction in glycated hemoglobin that was maintained throughout the study.
Higher magnesium intake was linked to a 15% lower risk for type 2 diabetes.
Overall reduction in HbA1c was higher in people with T2D vs those with T1D.
New monitoring system involves the placement of a small sensor wire beneath the skin surface to continuously monitor glucose levels.
Researchers examined the efficacy of lifestyle intervention on glycemic control in type 2 diabetes.
GlaxoSmithKline expects Tanzeum supplies to be depleted by July 2018.
Approval for the new indication follows a review of the results of the LEADER trial.
Sodium-glucose cotransporter 2 inhibitors reduced both systolic and diastolic blood pressure in patients with type 2 diabetes.
One hundred fifteen patients used the FreeStyle Libre Pro sensor to monitor interstitial fluid glucose for 14 days.
A randomized double-blind trial examined the safety and efficacy of ertugliflozin plus metformin for inadequately controlled type 2 diabetes.
Canagliflozin reduced levels of cardiovascular stress biomarkers N-terminal pro-B type natriuretic peptide and high sensitivity troponin I.
Patients with type 2 diabetes had lower rates of heart failure hospitalization, MACE, and all-cause mortality when treated with dapagliflozin.
No between-group differences for factors such as glycemic control, endogenous glucose production, and insulin sensitivity were found.
Results of 2 large clinical trials confirmed previous safety concerns surrounding canagliflozin therapy for type 2 diabetes.
The combined treatment regimen of metformin and liraglutide led to complete remission in 74% of patients with new onset type 2 diabetes.
Early initiation of insulin therapy in patients with type 2 diabetes improved HbA1c, fasting blood sugar, postprandial blood sugar, and BMI.
Researchers examined 24-hour and ambulatory blood pressure to determine the relationship between hypertension and low levels of vitamin D.
A comprehensive systematic review analyzes whether specific sodium-glucose cotransporter 2 inhibitors were more likely to be associated with adverse renal events in patients with type 2 diabetes.
A cohort study of primary care records in the United Kingdom did not find an increased risk of major cardiovascular events in patients with type 2 diabetes treated with insulin.
Researchers found that those at risk for low vitamin B12 levels are often not properly monitored.
Endocrinology Advisor Articles
- FDA Approves Admelog Short-Acting Insulin Lispro Injection
- Fertility Hormone Therapy and Cardiovascular Outcomes: What We Know
- Effects of Peer Influence in Adolescents With Type 1 Diabetes
- More Evidence That Saxagliptin Does Not Increase Risk for AMI in Diabetes
- One-Hour Glucose Readings Predict T2D Risk Better Than 2-Hour Measurements
- FDA: Vitamin B7 May Interfere With Lab Tests for Hormone Levels
- Injected and Oral Medications Equally Safe for Gestational Diabetes
- Adjunctive Dapagliflozin Improves Glycemic Control in T1D
- Estradiol Therapy May Benefit Overall Cognition in Postmenopausal Women
- Stopping Postmenopausal HT May Increase Risk for Cardiac, Stroke Death
- Psychosocial Benefits of a Bihormonal Bionic Pancreas System in T1D
- Safety of Chronic Total Occlusion Percutaneous Coronary Intervention in Diabetes
- Oral Insulin Not a Reliable Preventive Strategy for Type 1 Diabetes
- Prevention of Bone Mineral Density Loss Needed in Epilepsy
- Gastric Bypass Blunts B-Cell Sensitivity During Glycemia